VC
Switzerland
Last deal Apr 2026

Integra Holdings: Pre-Seed to Seed

Investment focus

Sectors

Investment stages

Geographic focus

Inferred thesis

Auto-generated from public data. Not the firm's stated position.

Integra Holdings appears to focus on early-stage biotech investments, particularly in therapeutic modalities including immuno-oncology, genetic treatments, and advanced medical devices. Recent portfolio suggests a preference for companies addressing unmet needs in oncology and rare genetic diseases, with check sizes typically ranging from €0.1M to €1.5M at pre-seed and seed stages.

Generated 1 Oct 2026 from disclosed sectors, stages, and portfolio companies. Is this your firm? Claim the profile to correct it.

How to Pitch Integra Holdings

No stated policy
Integra Holdings hasn't published an outreach policy. A short, specific cold email is the safest default.

Recent investments

Auto-extracted from press releases.

Portfolio highlights

Integra Holdings

Focus and check size from the firm's website. Website reachable as of Oct 2026.

Ready to reach Integra Holdings?

Red-pen your deck first so the gaps are fixed before they read it. A fit check then scores your pitch against their thesis, stage and ticket, and an email draft uses their real deals and thesis, not a template.